The Globe and Mail reports in its Thursday, Dec. 4, edition that ATB Capital Markets analyst Frederico Gomes has elevated his recommendation for Curaleaf Holdings. The Globe's David Leeder writes in the Eye On Equities column that Mr. Gomes gave his share target a 50-cent boost to $4.50. Analysts on average target the shares at $5.03. Mr. Gomes says in a note: "We [view Curaleaf's] recent valuation pullback as a compelling entry point into the sector's only true global platform. Curaleaf distinguishes itself through large domestic scale and unique leading presence in high-growth international markets (Germany, U.K., Poland) -- a strategic exposure that domestic-only peers lack. While EBITDA margins (low-20s) currently trail toptier operators and the balance sheet leverage remains a near-term friction point, we view this 'margin gap' as a catch-up opportunity that supports higher adj. EBITDA CAGR over the next five years. We believe the market still underappreciates the long-term value of the international segment as it scales. With a more constructive 2026/27 industry backdrop (on the intoxicating hemp ban) and continued international growth, we believe the stock deserves a premium multiple."